T细胞调定点抑制剂在肺癌患者的应用.pptx

T细胞检查点抑制剂——肺癌免疫靶向治疗;肺癌免疫治疗;肺癌免疫治疗;Immuno-Oncology;;T细胞检查点抑制剂;抗CTLA-4抗体– Ipilimumab;Mechanism of Action of Ipilimumab;Ipilimumab in Melanoma: MDX-20;;Ipilimumab in NSCLC-CA184-041;Study met primary end-point (A) Phased schedule significantly improved irPFS, HR = 0.72 (B) No significant improvement for concurrent schedule;Ipilimumab in NSCLC-CA184-041;Ipilimumab in NSCLC-CA184-041;Phased schedule shows trend for improved OS Confirmed in ad hoc analysis with longer follow-up No trend for concurrent schedule;Ipilimumab-Phase III trails;抗PD1抗体- Nivolumab;;;NSCLC cohort in Nivolumab phase 1/2 study (CA209003);Similar ORR in squamous (16.7%) and non-squamous (17.6%) NSCLC;Immune-related adverse event (irAE);;黑色素瘤汇总2期研究数据10 mg/kg 单药治疗（n=325）;irAE;irAE;Immune-related response criteria(irRC);irRC;Tumor volume increase due to lymphocyte infiltration;;CASE;CASE;血免疫指标监测;